Literature DB >> 28445018

First Case of Skin and Soft Tissue Infection Caused by Mycoplasma hominis in a Pediatric Immunocompromised Patient.

Hanwool Cho1, Kang Gyun Park1, Seong Beom Han2, Nack Gyun Chung2, Yeon Joon Park3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28445018      PMCID: PMC5409028          DOI: 10.3343/alm.2017.37.4.346

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


× No keyword cloud information.
Dear Editor, Mycoplasma hominis is a part of the urogenital commensal flora, with higher bacterial loads in women compared with men. Thus, infections of M. hominis are usually associated with endocervicitis and pelvic inflammatory diseases. Although rare, M. hominis can also cause various extra-urogenital infections, such as skin and soft tissue infections (SSTIs) [12], central nervous system (CNS) infection, mediastinitis, and disseminated infection [3456]. Because M. hominis lacks a cell wall and shows resistance to cell wall-acting antibiotics, including carbapenem and glycopeptides, it is important to accurately identify this bacterium and initiate appropriate treatment in the case of infection. Clindamycin shows the highest in vitro activity against M. hominis, followed by fluoroquinolones [4]. A 13-yr-old girl with aplastic anemia was admitted to the Seoul St. Mary's Hospital, Korea, for allogeneic hematopoietic cell transplantation (HCT). On HCT day 6, the patient developed a fever, but all culture analyses, including blood, urine, and sputum, were negative. It was presumed that the fever was caused by acute graft-versus-host disease (GvHD), considering the presence of a skin rash and diarrhea that accompanied the symptoms. The intravenous antibiotic treatment (meropenem, teicoplanin) was continued because of her immune-compromised state. However, gastrointestinal (GI) symptoms were aggravated, and thus methylprednisolone, methotrexate, and cyclophosphamide were added to the treatment. Despite these treatment efforts, bloody diarrhea and fever persisted. On HCT day 28, a colonoscopy and random biopsies were performed to identify the cause of bloody diarrhea, and the biopsies showed findings consistent with acute GvHD and positive immunohistochemical (IHC) staining for cytomegalovirus (CMV). CMV was also detected in the blood by real-time quantitative PCR (RQ-PCR) (AccuPower CMV Quantitative PCR, Bioneer, Daejeon, Korea). After treatment (ganciclovir) for two months, the CMV disappeared, which was confirmed by biopsies and blood RQ-PCR. During the high-intensity immunosuppressive therapy, multifocal skin abrasions in the perianal area occurred because of persistent diarrhea. On HCT day 120, pressure sores developed on the buttocks. Vancomycin and amphotericin B were added to the regimen to treat these lesions. However, painful swelling in the left inguinal area and a high fever developed on HCT day 127; thus, antibiotic therapy was changed to tigecycline and arbekacin. A core needle biopsy was performed, and pus was aspirated. A Gram stain from this aspiration revealed no microorganisms. The specimen was inoculated on blood agar plates (BAPs), MacConkey agar plates, chocolate agar plates, and Brucella broth, and cultured both aerobically (35℃ in 5% CO2) and anaerobically. After two days of incubation, the growth of pinpoint and translucent colonies was observed on the BAP cultured anaerobically. Gram staining of these colonies revealed no microorganisms. For identification with Vitek mass spectrometry (MS), a colony was picked up and placed on a target plate (Vitek MS-DS, bioMérieux, Marcy-l'Étoile, France), and 1 µL of the α-cyano-4-hydroxycinnamic acid solution (CHCA) matrix solution (bioMérieux) was applied to the spot. M. hominis was identified by using the Vitek MS IVD v2.0 database (bioMérieux) (Fig. 1). This result was confirmed by real-time PCR (GeneFinder, Infopia, Anyang, Korea). In addition, the Mycoplasma IST2 kit (bioMérieux) showed the growth of <104 M. hominis, which was susceptible to doxycycline, josamycin, ofloxacin, ciprofloxacin, and pristinamycin. Accordingly, the antibiotic treatment was changed to levofloxacin; however, the patient died owing to uncontrolled GvHD and SSTI on hospital day 141.
Fig. 1

Result of matrix-assisted laser desorption/ionization time of flight (MALDI TOF)-mass spectrometry for the identification of Mycoplasma hominis.

Abbreviations: m, mass; z, charge; Da, Dalton.

In this case, we presume that the urethral catheterization might have been the route of bacterial invasion. Although the rate of genital colonization of M. hominis in sexually inactive women is significantly lower than that in sexually active women [7], we report an immunocompromised prepubescent patient with SSTI caused by M. hominis. Identification of M. hominis infections by culture is challenging because it is a fastidious process, and the median time needed for the growth of M. hominis is six days [3]. Therefore, when a Gram stain reveals abundant neutrophils but no bacteria, clinical microbiologists should suspect the possibility of infection caused by Mycoplasma, and use of special media (IST2 kit and A7, A8 agar) and culture period extension should be considered. Direct molecular detection from the specimen can be an alternative method. The suitability of matrix-assisted laser desorption-time-of-flight MS for the identification of M. hominis is controversial [468]. Identification using molecular methods such as 16S rDNA sequencing can also be used [6]. In conclusion, the prevalence of infections caused by M. hominis might be underestimated because of the difficulty in identifying this potential pathogen in routine microbiological analyses. This case highlights the need for early diagnosis M. hominis infection and the importance of initial appropriate chemotherapy, especially in immunocompromised hosts.
  8 in total

1.  Lumbar pain caused by Mycoplasma infection.

Authors:  S Kayser; H J Bhend
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

2.  A case report of Mycoplasma hominis brain abscess identified by MALDI-TOF mass spectrometry.

Authors:  H Pailhoriès; V Rabier; M Eveillard; C Mahaza; M-L Joly-Guillou; J-M Chennebault; M Kempf; C Lemarié
Journal:  Int J Infect Dis       Date:  2014-10-24       Impact factor: 3.623

3.  Extragenital Mycoplasma hominis infection: a report of two cases.

Authors:  D R Shaw; I Lim
Journal:  Med J Aust       Date:  1988-02-01       Impact factor: 7.738

4.  Identification and subtyping of clinically relevant human and ruminant mycoplasmas by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  S Pereyre; F Tardy; H Renaudin; E Cauvin; L Del Prá Netto Machado; A Tricot; F Benoit; M Treilles; C Bébéar
Journal:  J Clin Microbiol       Date:  2013-07-31       Impact factor: 5.948

5.  A new case of Mycoplasma hominis mediastinitis and sternal osteitis after cardiac surgery.

Authors:  Rémi Le Guern; Caroline Loïez; Valentin Loobuyck; Natacha Rousse; René Courcol; Frédéric Wallet
Journal:  Int J Infect Dis       Date:  2014-12-19       Impact factor: 3.623

6.  Hormonal status and mycoplasma colonization in the female genital tract.

Authors:  T Iwasaka; T Wada; Y Kidera; H Sugimori
Journal:  Obstet Gynecol       Date:  1986-08       Impact factor: 7.661

7.  A disseminated Mycoplasma hominis infection in a patient with an underlying defect in humoral immunity.

Authors:  Eric Nulens; Jens Van Praet; Dominik Selleslag; Thomas Van Landschoot; Dieter Dekeyzer; Patrick Descheemaecker; Marijke Reynders
Journal:  Infection       Date:  2015-11-06       Impact factor: 3.553

Review 8.  Meningitis in a Chinese adult patient caused by Mycoplasma hominis: a rare infection and literature review.

Authors:  Menglan Zhou; Peng Wang; Sharon Chen; Bin Du; Jinlong Du; Fengdan Wang; Meng Xiao; Fanrong Kong; Yingchun Xu
Journal:  BMC Infect Dis       Date:  2016-10-12       Impact factor: 3.090

  8 in total
  1 in total

Review 1.  An Update in Antimicrobial Therapies and Infection Prevention in Pediatric Lung Transplant Recipients.

Authors:  O C Smibert; M A Paraskeva; G Westall; Greg Snell
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.